FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141134100> ?p ?o ?g. }

• W2141134100 endingPage "11511" @default.
• W2141134100 startingPage "11507" @default.
• W2141134100 abstract "Cathepsins K and L are related cysteine proteases that have been proposed to play important roles in osteoclast-mediated bone resorption. To further examine the putative role of cathepsin L in bone resorption, we have evaluated selective and potent inhibitors of human cathepsin L and cathepsin K in an in vitro assay of human osteoclastic resorption and an in situ assay of osteoclast cathepsin activity. The potent selective cathepsin L inhibitors (Ki = 0.0099, 0.034, and 0.27 nm) were inactive in both the in situcytochemical assay (IC50 > 1 μm) and the osteoclast-mediated bone resorption assay (IC50 > 300 nm). Conversely, the cathepsin K selective inhibitor was potently active in both the cytochemical (IC50 = 63 nm) and resorption (IC50 = 71 nm) assays. A recently reported dipeptide aldehyde with activity against cathepsins L (Ki = 0.052 nm) and K (Ki = 1.57 nm) was also active in both assays (IC50 = 110 and 115 nm, respectively) These data confirm that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption. Cathepsins K and L are related cysteine proteases that have been proposed to play important roles in osteoclast-mediated bone resorption. To further examine the putative role of cathepsin L in bone resorption, we have evaluated selective and potent inhibitors of human cathepsin L and cathepsin K in an in vitro assay of human osteoclastic resorption and an in situ assay of osteoclast cathepsin activity. The potent selective cathepsin L inhibitors (Ki = 0.0099, 0.034, and 0.27 nm) were inactive in both the in situcytochemical assay (IC50 > 1 μm) and the osteoclast-mediated bone resorption assay (IC50 > 300 nm). Conversely, the cathepsin K selective inhibitor was potently active in both the cytochemical (IC50 = 63 nm) and resorption (IC50 = 71 nm) assays. A recently reported dipeptide aldehyde with activity against cathepsins L (Ki = 0.052 nm) and K (Ki = 1.57 nm) was also active in both assays (IC50 = 110 and 115 nm, respectively) These data confirm that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption. Osteoclasts are multinucleated cells of hematopoietic origin that are responsible for resorbing bone (1Walker D.G. Science. 1973; 180: 275Crossref Scopus (131) Google Scholar, 2Kahn A.J. Simmons D.J. Nature. 1975; 258: 325-327Crossref PubMed Scopus (165) Google Scholar). Following tight attachment to the bone surface, osteoclasts begin the resorptive process by secreting protons into the extracellular space (3Baron R. Neff L. Louvard D. Courtoy P.J. J. Cell Biol. 1985; 101: 2210-2222Crossref PubMed Scopus (594) Google Scholar), which results in the removal of bone mineral and the exposure of the underlying matrix. It also provides optimal conditions for the activity of osteoclast-derived proteases that ultimately solubilize these matrix components, which include type I collagen, osteopontin, osteonectin, and other components. The identification of the key enzyme(s) responsible for this protein matrix degradation is essential for understanding the mechanisms of bone metabolism and for the design of inhibitors of the resorptive process for the intervention of metabolic bone diseases such as osteoporosis. Numerous reports have suggested that cathepsin L and/or cathepsin K may be the major proteases involved in this process (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar, 5Drake F.H. Dodds R.A. James I.E. Connor J.R. Debouck C. Richardson S. Lee-Rykaczewski E. Coleman L. Rieman D. Barthlow R. Hastings G. Gowen M. J. Biol. Chem. 1996; 271: 12511-12516Abstract Full Text Full Text PDF PubMed Scopus (619) Google Scholar, 6Yasuma T. Oi S. Choh N. Nomura T. Furuyama N. Nishimura A. Fujisawa Y. Sohda T. J. Med. Chem. 1998; 41: 4301-4308Crossref PubMed Scopus (78) Google Scholar). However, recent studies have indicated that mRNA for cathepsin L is undetectable in human osteoclasts (5Drake F.H. Dodds R.A. James I.E. Connor J.R. Debouck C. Richardson S. Lee-Rykaczewski E. Coleman L. Rieman D. Barthlow R. Hastings G. Gowen M. J. Biol. Chem. 1996; 271: 12511-12516Abstract Full Text Full Text PDF PubMed Scopus (619) Google Scholar), and the cathepsin L null mouse does not show a bone-related phenotype (7Hart K.A. Potts W. Bowyer J. Slynn G. Elston P. Vernon W. Tucker K. Johnstone D. J. Bone Miner. Res. 1996; 11: S181Google Scholar). In contrast, it has been reported that the knockout of cathepsin K results in osteopetrosis that is characterized by osteosclerosis (8Saftig P. Huntziger E. Wehmeyer O. Jones S. Boyde A. Romerskirch W. Moritz J. Schu P. von Figura K. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13453-13458Crossref PubMed Scopus (751) Google Scholar, 9Gowen M. Lazner F. Dodds R. Kapadia R. Field J. Tavaria M. Bertoncello I. Drake F. Zavarselk S. Tellis I. Hertzog P. Debouck C. Kola I. J. Bone Miner. Res. 1999; 14: 1654-1663Crossref PubMed Scopus (418) Google Scholar). Both microcomputerized tomography and histomorphometry indicate an increase in trabecular number and in trabecular and cortical thickening in the knockout animals when compared with their wild-type littermates (9Gowen M. Lazner F. Dodds R. Kapadia R. Field J. Tavaria M. Bertoncello I. Drake F. Zavarselk S. Tellis I. Hertzog P. Debouck C. Kola I. J. Bone Miner. Res. 1999; 14: 1654-1663Crossref PubMed Scopus (418) Google Scholar). Furthermore, this mutation leads to the elimination of all osteoclast-related cathepsin activity and ultimately to a reduction in osteoclast-mediated matrix degradation. The importance of cathepsin K in the resorptive process is further supported by a rare skeletal disorder in humans called pyknodysostosis, which occurs as a result of mutations in the cathepsin K gene, resulting in elimination of cathepsin K activity (10Gelb B.D. Shi G.-P. Chapman H.A. Desnick R.J. Science. 1996; 273: 1236-1238Crossref PubMed Scopus (851) Google Scholar). The disorder is characterized by a reduction in the rate of bone turnover, which leads to poor quality dense bone that is predisposed to fracture (11Elmore S.M. Nance W.E. McGee B.J. Montmollin M.E. Engel E. Am. J. Med. 1966; 40: 273-282Abstract Full Text PDF PubMed Scopus (26) Google Scholar, 12Meredith S.C. Simon M.A. Laros G.S. Jackson M.A. J. Bone Jt. Surg. Am. 1978; 60: 1122-1127Crossref PubMed Scopus (30) Google Scholar). Other skeletal manifestations of the disorder include a dysplasia in the bones of the face and clavicle, abnormal tooth eruption, and a lack of closure in the cranial sutures. Several reports claim that potent and selective inhibitors of cathepsin L are able to inhibit bone resorption both in vitro andin vivo (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar, 6Yasuma T. Oi S. Choh N. Nomura T. Furuyama N. Nishimura A. Fujisawa Y. Sohda T. J. Med. Chem. 1998; 41: 4301-4308Crossref PubMed Scopus (78) Google Scholar). Similarly, several studies suggest that small molecule inhibitors of cathepsin K are also capable of inhibitingin vitro and in vivo bone resorption (13Votta B.J. Levy M.A. Badger A. Bradbeer J. Dodds R.A. James I.E. Thompson S. Bossard M.J. Carr T. Connor J.R. Tomaszek T.A. Szewczuk L. Drake F.H. Veber D.F. Gowen M. J. Bone Miner. Res. 1997; 12: 1396-1406Crossref PubMed Scopus (164) Google Scholar, 14Thompson S.K. Halbert S.M. Bossard M.J. Tomaszek T.A. Levy M.A. Zhaou B. Smith W.W. Abdel-Meguid S.S. Janson C.A. D'Alessio K.J. McQueney M.S. Amegadzie B.Y. Hanning C.R. DesJarlais R.L. Briand J. Sarkar S.K. Huddleston M.J. Ijames C.F. Carr S.A. Garnes K.T. Shu A. Heys J.R. Bradbeer J. Zembryki D. Lee- Rykaczewski L. James I.E. Lark M.W. Drake F.H. Gowen M. Gleason J.G. Veber D.F. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 14249-14254Crossref PubMed Scopus (126) Google Scholar). In this study, we address this discrepancy and determine the relative importance of cathepsins L and K in human osteoclast-mediated bone resorption. In the course of a program directed at specific inhibition of cathepsin K, we have discovered several inhibitors that are selective for this enzyme, but we also have found selective inhibitors of cathepsin L. We also have studied the inhibitor of Woo et al. (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar) that we find to be a potent inhibitor of both cathepsins L and K. Nonselective inhibitors from our inhibitor collection have also been studied. Our data suggest that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption. Inhibition of human cathepsin K activity was measured as previously described (13Votta B.J. Levy M.A. Badger A. Bradbeer J. Dodds R.A. James I.E. Thompson S. Bossard M.J. Carr T. Connor J.R. Tomaszek T.A. Szewczuk L. Drake F.H. Veber D.F. Gowen M. J. Bone Miner. Res. 1997; 12: 1396-1406Crossref PubMed Scopus (164) Google Scholar). Inhibition of cathepsin L was measured under identical experimental conditions using the substrateZ-Phe-Arg-aminomethylcoumarin. As appropriate, linear portions of the initial velocity data from product progress curves were analyzed to generate steady-state constants. A standard curve with AMC was used in the conversion of fluorescence to molar units. Human osteoclastoma tissue (Jefferson Hospital, Philadelphia, PA) was obtained (with informed consent) at the time of surgery and frozen as described previously (15Dodds R.A. Connor J.R. James I.E. Arnett T.R. Henderson B. Methods in Bone Biology. Chapman & Hall, London1998: 198-238Google Scholar). Cryostat sections (7 μm) were cut on a Hacker cryostat (Hacker Instruments, Inc., Fairfield, NJ) equipped with a finely polished tungsten-tipped steel knife and flash-dried onto glass 4-well slides. Cryostat sections of human osteoclastoma were assayed for cathepsin activity using a slightly modified version of the azo-coupling procedure described by Dodds et al. 1Dodds, R. A., James, I. E., Rieman, D., Ahern, R., Hwang, S. M., Connor, J. R., Thompson, S. D., Veber, D. F., Drake, F. H., Holmes, S., Lark, M. W., and Gowen, M. (2001) J. Bone Miner. Res.16, 478–486. Each section was incubated in the presence or absence of inhibitors (0.01–1 μm) for 10 min at 37 °C in 150 μl of the following reaction medium: 20% polypeptide (Sigma) in 0.1 mphosphate buffer, pH 5.5, containing 2.5 mm EDTA and 7 mm substrate Ac-Leu-Arg-4-methoxy-β-naphthylamide. The medium was removed, and the sections were postcoupled with 0.25 mg/ml Fast Blue B Base (Sigma) for 10 min at room temperature. The sections were then rinsed in phosphate-buffered saline and finally incubated for 10 min at room temperature with 100 mm CuSO4. The reaction product was measured on a per cell basis (× 40 objective at 550 nm) in a minimum of 10 osteoclasts in duplicate sections of osteoclastoma using a Vickers M85 scanning and integrating microdensitometer as described previously.1 Results are presented as IC50 for individual inhibitors as calculated from the resulting dose response curves. Human osteoclastoma-derived osteoclasts were isolated as previously described (17James I.E. Dodds R.A. Lee-Rykaczewski E. Eichman C.F. Connor J.R. Hart T.K. Maleeff B.E. Lackman R.D. Gowen M. J. Bone Miner. Res. 1996; 11: 1608-1618Crossref PubMed Scopus (45) Google Scholar) and were used in an in vitro bone resorption assay (18James I.E. Lark M.W. Zembryki D. Lee-Rykaczewski E.V. Hwang S.M. Tomaszek T.A. Belfiore P. Gowen M. J. Bone Miner. Res. 1999; 14: 1562-1569Crossref PubMed Scopus (42) Google Scholar). Isolated osteoclast-enriched cell preparations were seeded onto bovine cortical bone slices in the presence of compound (0.001–3 mm) or vehicle (dimethyl sulfoxide) for 48 h at 37 °C. Compounds were not tested at concentrations higher than 3 mm, because the vehicle is inhibitory at high concentrations. The culture supernatants were harvested, and the levels of the C-terminal peptide of the α-1 chain of human type I collagen were quantified with a biochemical readout of resorption using a second generation one-step enzyme-linked immunosorbent assay (Osteometer Biotech A/S, Herlev, Denmark). This is a modification of the original competitive assay described by Foged et al. (19Foged N.T. Delaisse J.-M. Hou P. Lou H. Sato T. Winding B. Bonde M. J. Bone Miner. Res. 1996; 11: 226-237Crossref PubMed Scopus (61) Google Scholar). The results are expressed as percent inhibition of resorption. The IC50 values were determined from the resultant dose response curves. The compounds were synthesized in the Department of Medicinal Chemistry (SmithKline Beecham). Details of the design and synthesis of these compounds will be reported elsewhere. SB 412515, a potent cathepsin L and cathepsin K inhibitor, was originally synthesized and described by Woo et al. (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar). SB 290190, a potent and selective cathepsin K inhibitor, is described by Veberet al. (20Veber D.F. Yamashita D.S. Oh H.-J. Smith B.R. Salyers K. Lee C.-P. Marzulli A. Smith P. Tomaszek T. Tew D. McQueney M. Stroup G.B. Lark M.W. James I.E. Gowen M. Fields G.B. Tam J.P. Barany G Peptides for the New Millenium: Proceeding of the 16th American Peptide Symposium. Kluwer Academic Publishers Group, Dordrecht, The Netherlands2000: 453-455Google Scholar). The human cathepsin L inhibitors (SB 468420, SB 468432, and SB 468433 in TableI) used in this study are very potent inhibitors of this enzyme (Ki = 0.0099 ± 0.0003, 0.033 ± 0.006, and 0.272 ± 0.026 nm, respectively) and demonstrate impressive selectivity compared with the closely related cysteine protease, human cathepsin K (66- to >50,000-fold selectivity). The dipeptide aldehyde SB 412515 is also a potent cathepsin L inhibitor (Ki = 0.052 ± 0.002 nm), but it also shows activity against cathepsin K (Ki = 1.57 ± 0.367 nm, Table I). This compound was originally described as a potent cathepsin L inhibitor (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar), but no data were presented showing its activity against human cathepsin K. In contrast, SB 290190 is a potent inhibitor of cathepsin K (Ki = 0.050 ± 0.050 nm) and shows ∼72-fold selectivity over cathepsin L (Ki = 3.58 nm, Table I). The data in Table I are presented as Ki ± S.D.Table IEnzyme inhibitory activity of the cathepsin inhibitors Open table in a new tab To determine whether the cathepsin L selective inhibitors could inhibit native osteoclast cathepsins within whole tissue sections of human osteoclastoma, the compounds were evaluated in an in situ cytochemical assay using the cathepsin K/L substrate, Ac-Leu-Arg-4M-β-naphthylamide. Using this assay none of the cathepsin L selective compounds at concentrations of up to 1 μminhibited enzyme activity (Table II). The selective cathepsin L inhibitors also failed to decrease bone resorption at all concentrations tested (0.001–300 nm, Table II), even though their potency against cathepsin L ranged fromKi = 0.097 nm to Ki=1.7 nm (Table I). In contrast, SB 290190, a potent and selective cathepsin K inhibitor (Ki = 0.050 ± 0.005 nm), showed potent inhibition of osteoclast cathepsin activity in the cytochemical assay (Fig.1, IC50 = 63 ± 4 nm), and this activity translated into potent inhibition of bone resorptive activity in the in vitro resorption assay (Fig. 1, IC50 = 71 ± 25 nm, Table II, and Fig. 2). Significantly, SB 412515, a compound that had been reported previously as a selective inhibitor of cathepsin L (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar), also demonstrated potent activity in both the in situ cytochemical assay (IC50 = 110 ± 5 nm) and the in vitro resorption assay (IC50 = 115 ± 40 nm). Subsequent measurement of the enzyme inhibitory activity of this compound revealed that it is a potent inhibitor of both human cathepsins K and L. Together these data indicate that inhibition of cathepsin K is required for the inhibition of bone resorption in vitro. Potent inhibition of cathepsin L without cathepsin K inhibition has no effect on this process.Table IIPotent and selective cathepsin L inhibitors do not block cathepsin activity or in vitro resorption by human osteoclasts Open table in a new tab Figure 2SB 412515, a potent dual cathepsin L and cathepsin K inhibitor, restricts in vitro human osteoclast-mediated resorption and in situ cathepsin activity. The compound was tested in the human osteoclast resorption (n = 4) (A) and cathepsin cytochemical assays (n = 4) (B). The compound was active in both assays and showed similar potency. The data are presented as percent inhibition ± S.E.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Conflicting data suggest that cathepsin L may play a pivotal role in human osteoclast-mediated resorption. This study was designed to determine whether potent and selective inhibitors of this protease can indeed inhibit the resorptive process and to contrast them with potent and selective cathepsin K inhibitors. The data presented here show a lack of inhibition of both human osteoclast cathepsin activity and resorption by these selective cathepsin L inhibitors. In contrast, the compounds that show potent inhibition of cathepsin K (with some cathepsin L inhibitory activity) potently inhibit cathepsin activity and resorption in human osteoclasts. Taken together, these data indicate that cathepsin K is the single most important protease in human osteoclast-mediated bone resorption and that cathepsin L is not likely to play a role in this process. The pivotal role for cathepsin K in osteoclast-mediated bone matrix degradation has been described using multiple approaches. Northern blot (16Inaoka T. Bilbe G. Ishibashi O. Tezuka K.-I. Kamegawa M. Kokubo T. Biochem. Biophys. Res. Commun. 1995; 206: 89-96Crossref PubMed Scopus (320) Google Scholar, 21Bromme D. Okamoto K. Biol. Chem. Hoppe-Seyler. 1995; 376: 379-384Crossref PubMed Scopus (241) Google Scholar) and in situ hybridization (5Drake F.H. Dodds R.A. James I.E. Connor J.R. Debouck C. Richardson S. Lee-Rykaczewski E. Coleman L. Rieman D. Barthlow R. Hastings G. Gowen M. J. Biol. Chem. 1996; 271: 12511-12516Abstract Full Text Full Text PDF PubMed Scopus (619) Google Scholar) studies have demonstrated that cathepsin K mRNA is abundant in osteoclasts. Immunocytochemical studies, using an anti-cathepsin K antibody, indicate that the enzyme is present in osteoclasts opposed to the bone surface (5Drake F.H. Dodds R.A. James I.E. Connor J.R. Debouck C. Richardson S. Lee-Rykaczewski E. Coleman L. Rieman D. Barthlow R. Hastings G. Gowen M. J. Biol. Chem. 1996; 271: 12511-12516Abstract Full Text Full Text PDF PubMed Scopus (619) Google Scholar). Furthermore, the enzyme is activated as the cells approach bone and distributed in a polarized fashion to the surface of the cell that interacts with the bone surface. In contrast, in situhybridization studies have shown that mRNA for cathepsins L, B, and S is undetectable in human osteoclasts (5Drake F.H. Dodds R.A. James I.E. Connor J.R. Debouck C. Richardson S. Lee-Rykaczewski E. Coleman L. Rieman D. Barthlow R. Hastings G. Gowen M. J. Biol. Chem. 1996; 271: 12511-12516Abstract Full Text Full Text PDF PubMed Scopus (619) Google Scholar). Mutations in the cathepsin K gene also indicate the importance of cathepsin K in the resorptive process. The cathepsin K knockout mouse (8Saftig P. Huntziger E. Wehmeyer O. Jones S. Boyde A. Romerskirch W. Moritz J. Schu P. von Figura K. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13453-13458Crossref PubMed Scopus (751) Google Scholar, 9Gowen M. Lazner F. Dodds R. Kapadia R. Field J. Tavaria M. Bertoncello I. Drake F. Zavarselk S. Tellis I. Hertzog P. Debouck C. Kola I. J. Bone Miner. Res. 1999; 14: 1654-1663Crossref PubMed Scopus (418) Google Scholar) and the human disease, pyknodysostosis (10Gelb B.D. Shi G.-P. Chapman H.A. Desnick R.J. Science. 1996; 273: 1236-1238Crossref PubMed Scopus (851) Google Scholar), are characterized by marked osteopetrosis as a result of retarded osteoclastic bone resorption. In contrast, a null mutation in the cathepsin L gene that resulted in mice lacking cathepsin L mRNA and biological activity did not present with bone abnormalities (7Hart K.A. Potts W. Bowyer J. Slynn G. Elston P. Vernon W. Tucker K. Johnstone D. J. Bone Miner. Res. 1996; 11: S181Google Scholar). We have previously described the development and characterization of a human in vitro resorption assay that uses osteoclastoma-derived osteoclasts (18James I.E. Lark M.W. Zembryki D. Lee-Rykaczewski E.V. Hwang S.M. Tomaszek T.A. Belfiore P. Gowen M. J. Bone Miner. Res. 1999; 14: 1562-1569Crossref PubMed Scopus (42) Google Scholar). This assay provides a robust and reproducible system for the evaluation of inhibitors of osteoclast-mediated bone resorption including the inhibitors of cathepsin K. The potency of the cathepsin K compounds correlates strongly with the activity against recombinant human cathepsin K enzyme activity (r2 = 0.80). In addition to the resorption assay, we recently described the development of a quantitative cytochemical assay that measures cathepsin activity in osteoclasts in sections of human tissue.1 Previous studies using this assay on bone from cathepsin K knockout mice1indicated that cathepsin K was the enzyme activity being measured within osteoclasts in this assay. Consequently, the cathepsin cytochemical assay provides confirmation of the activity of the cathepsin K inhibitors in the resorption assay and is an essential part of our screen for potential cathepsin K inhibitors. It has been reported previously by Woo et al. (4Woo J.-T. Yamaguchi K. Hayami T. Kobori T. Sigeizumi S. Sugimoto K. Kondo K. Tsuji T. Ohba Y. Tagami K. Sumitani K. Eur. J. Pharmacol. 1996; 300: 131-135Crossref PubMed Scopus (34) Google Scholar) that the dipeptidyl aldehyde SB 412515 was a potent cathepsin L inhibitor that could inhibit both in vitro and in vivo bone resorption. Although this report describes the compound as a more potent inhibitor for cathepsin L than other cysteine proteases, such as cathepsin B and calpain II, its inhibition of cathepsin K was not reported. Similarly, Yasuma et al. (6Yasuma T. Oi S. Choh N. Nomura T. Furuyama N. Nishimura A. Fujisawa Y. Sohda T. J. Med. Chem. 1998; 41: 4301-4308Crossref PubMed Scopus (78) Google Scholar) reports the preparation of a series of peptide aldehyde derivatives that demonstrated potent activity against cathepsin L; data were not reported for cathepsin K inhibition. One of these compounds inhibited bone resorption in vitro and prevented bone loss in the ovariectomized mouse (6Yasuma T. Oi S. Choh N. Nomura T. Furuyama N. Nishimura A. Fujisawa Y. Sohda T. J. Med. Chem. 1998; 41: 4301-4308Crossref PubMed Scopus (78) Google Scholar). Our enzyme activity studies revealed that SB 412515 had potent activity against human cathepsin K, as well as cathepsin L, and the compound from the Yasuma study (6Yasuma T. Oi S. Choh N. Nomura T. Furuyama N. Nishimura A. Fujisawa Y. Sohda T. J. Med. Chem. 1998; 41: 4301-4308Crossref PubMed Scopus (78) Google Scholar) is a potent inhibitor of both human and mouse cathepsin K (data not shown). The lack of activity of the cathepsin L selective compounds confirm that it is the potent cathepsin K activity of SB 412515 and SB 290190 that explains their potent antiresorptive activity. In conclusion, we demonstrate using two distinct in vitro assays of human osteoclast function that cathepsin L selective inhibitors are unable to inhibit human osteoclast cathepsin activity, and this results in a lack of inhibition of osteoclast-mediated bone resorption. In contrast, potent inhibitors of cathepsin K reproducibly inhibited osteoclast function thus providing unequivocal evidence that it is cathepsin K and not cathepsin L that plays the pivotal role in osteoclast-mediated matrix degradation. We thank Dr. Richard Lackman of the Jefferson Hospital (Philadelphia, PA) for supplying the osteoclastoma tissues." @default.
• W2141134100 created "2016-06-24" @default.
• W2141134100 creator A5002726689 @default.
• W2141134100 creator A5005493607 @default.
• W2141134100 creator A5011948735 @default.
• W2141134100 creator A5013116316 @default.
• W2141134100 creator A5017027336 @default.
• W2141134100 creator A5019768909 @default.
• W2141134100 creator A5023131186 @default.
• W2141134100 creator A5034863047 @default.
• W2141134100 creator A5037778058 @default.
• W2141134100 creator A5039671782 @default.
• W2141134100 creator A5041947462 @default.
• W2141134100 creator A5050948761 @default.
• W2141134100 creator A5084826778 @default.
• W2141134100 creator A5088231109 @default.
• W2141134100 date "2001-04-01" @default.
• W2141134100 modified "2023-09-27" @default.
• W2141134100 title "Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro" @default.
• W2141134100 cites W1967000705 @default.
• W2141134100 cites W1984965767 @default.
• W2141134100 cites W2025062557 @default.
• W2141134100 cites W2034733431 @default.
• W2141134100 cites W2039218698 @default.
• W2141134100 cites W2058616210 @default.
• W2141134100 cites W2075356469 @default.
• W2141134100 cites W2083294270 @default.
• W2141134100 cites W2089235682 @default.
• W2141134100 cites W2090013801 @default.
• W2141134100 cites W2130089634 @default.
• W2141134100 cites W2139865760 @default.
• W2141134100 cites W2155036500 @default.
• W2141134100 cites W2160174421 @default.
• W2141134100 cites W2161115679 @default.
• W2141134100 cites W2257243306 @default.
• W2141134100 cites W2333911447 @default.
• W2141134100 cites W2950998817 @default.
• W2141134100 doi "https://doi.org/10.1074/jbc.m010684200" @default.
• W2141134100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11148212" @default.
• W2141134100 hasPublicationYear "2001" @default.
• W2141134100 type Work @default.
• W2141134100 sameAs 2141134100 @default.
• W2141134100 citedByCount "30" @default.
• W2141134100 countsByYear W21411341002012 @default.
• W2141134100 countsByYear W21411341002017 @default.
• W2141134100 countsByYear W21411341002018 @default.
• W2141134100 crossrefType "journal-article" @default.
• W2141134100 hasAuthorship W2141134100A5002726689 @default.
• W2141134100 hasAuthorship W2141134100A5005493607 @default.
• W2141134100 hasAuthorship W2141134100A5011948735 @default.
• W2141134100 hasAuthorship W2141134100A5013116316 @default.
• W2141134100 hasAuthorship W2141134100A5017027336 @default.
• W2141134100 hasAuthorship W2141134100A5019768909 @default.
• W2141134100 hasAuthorship W2141134100A5023131186 @default.
• W2141134100 hasAuthorship W2141134100A5034863047 @default.
• W2141134100 hasAuthorship W2141134100A5037778058 @default.
• W2141134100 hasAuthorship W2141134100A5039671782 @default.
• W2141134100 hasAuthorship W2141134100A5041947462 @default.
• W2141134100 hasAuthorship W2141134100A5050948761 @default.
• W2141134100 hasAuthorship W2141134100A5084826778 @default.
• W2141134100 hasAuthorship W2141134100A5088231109 @default.
• W2141134100 hasBestOaLocation W21411341001 @default.
• W2141134100 hasConcept C101990758 @default.
• W2141134100 hasConcept C134018914 @default.
• W2141134100 hasConcept C146562846 @default.
• W2141134100 hasConcept C167844969 @default.
• W2141134100 hasConcept C181199279 @default.
• W2141134100 hasConcept C185592680 @default.
• W2141134100 hasConcept C202751555 @default.
• W2141134100 hasConcept C2776033226 @default.
• W2141134100 hasConcept C55493867 @default.
• W2141134100 hasConcept C673006 @default.
• W2141134100 hasConcept C86803240 @default.
• W2141134100 hasConcept C95444343 @default.
• W2141134100 hasConceptScore W2141134100C101990758 @default.
• W2141134100 hasConceptScore W2141134100C134018914 @default.
• W2141134100 hasConceptScore W2141134100C146562846 @default.
• W2141134100 hasConceptScore W2141134100C167844969 @default.
• W2141134100 hasConceptScore W2141134100C181199279 @default.
• W2141134100 hasConceptScore W2141134100C185592680 @default.
• W2141134100 hasConceptScore W2141134100C202751555 @default.
• W2141134100 hasConceptScore W2141134100C2776033226 @default.
• W2141134100 hasConceptScore W2141134100C55493867 @default.
• W2141134100 hasConceptScore W2141134100C673006 @default.
• W2141134100 hasConceptScore W2141134100C86803240 @default.
• W2141134100 hasConceptScore W2141134100C95444343 @default.
• W2141134100 hasIssue "15" @default.
• W2141134100 hasLocation W21411341001 @default.
• W2141134100 hasOpenAccess W2141134100 @default.
• W2141134100 hasPrimaryLocation W21411341001 @default.
• W2141134100 hasRelatedWork W2020087564 @default.
• W2141134100 hasRelatedWork W2070222842 @default.
• W2141134100 hasRelatedWork W2088132708 @default.
• W2141134100 hasRelatedWork W2126910264 @default.
• W2141134100 hasRelatedWork W2132517007 @default.
• W2141134100 hasRelatedWork W2141134100 @default.
• W2141134100 hasRelatedWork W2345282274 @default.
• W2141134100 hasRelatedWork W2403179950 @default.

• next